Immune checkpoint inhibitor (ICI) therapy is a type of treatment for melanoma, the deadliest form of skin cancer, which blocks proteins on tumor or immune cells that prevent the immune system from killing cancer cells. While this treatment has shown some clinical success in patients with advanced stages of melanoma, its efficacy depends on reliable predictors of a patient’s response to the therapy.
2022
Data Support Neoadjuvant and Adjuvant Pembrolizumab in Resectable Melanoma
The combination of neoadjuvant and adjuvant pembrolizumab appears more effective than adjuvant pembrolizumab alone for patients with resectable melanoma, according to a phase 2 study presented at ESMO Congress 2022.
Potential melanoma target bypasses therapeutic resistance to immune checkpoint blockers
Over the last decade, immune checkpoint blockers, or ICBs, have revolutionized treatment for various advanced cancers, including melanoma, the most aggressive skin cancer that was considered largely incurable not long ago.
Role of Precision Medicine in the Management of Melanoma
Precision medicine may help improve the diagnosis and management of melanoma.